All Updates

All Updates

icon
Filter
FDA approval
Orchard Therapeutics’ Lenmeldy receives FDA approval; becomes first-of-its kind treatment for children with genetic disorder
Cell & Gene Therapy
Mar 18, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Mar 18, 2024

Orchard Therapeutics’ Lenmeldy receives FDA approval; becomes first-of-its kind treatment for children with genetic disorder

FDA approval

  • UK-based Orchard Therapeutics has received FDA approval for gene therapy "Lenmeldy" to treat children suffering from metachromatic leukodystrophy (MLD), a rare genetic disease. The therapy's price has not been disclosed.

  • Lenmeldy is a one-time therapy for children experiencing certain stages of MLD and uses the patient's own hematopoietic stem cells. The FDA reported that Lenmeldy substantially reduced the risk of severe motor impairment or death compared to untreated children. In December 2020, the therapy was approved and marketed in the European Union under the brand name "Libmeldy."

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.